Sol-Gel Technologies Return on Tangible Equity 2016-2026 | SLGL
Current and historical return on tangible equity values for Sol-Gel Technologies (SLGL) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Sol-Gel Technologies Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2026-03-31 | $0.00B | $0.03B | -3.03% |
| 2025-12-31 | $-0.01B | $0.03B | -23.76% |
| 2025-09-30 | $-0.01B | $0.03B | -33.64% |
| 2025-06-30 | $0.00B | $0.03B | -10.34% |
| 2025-03-31 | $-0.01B | $0.03B | -43.70% |
| 2024-12-31 | $-0.01B | $0.03B | -30.30% |
| 2024-09-30 | $-0.01B | $0.04B | -25.35% |
| 2024-06-30 | $-0.02B | $0.04B | -40.00% |
| 2024-03-31 | $-0.02B | $0.04B | -56.44% |
| 2023-12-31 | $-0.03B | $0.04B | -64.37% |
| 2023-09-30 | $-0.03B | $0.04B | -65.54% |
| 2023-06-30 | $-0.03B | $0.05B | -57.46% |
| 2023-03-31 | $-0.02B | $0.05B | -43.72% |
| 2022-12-31 | $-0.02B | $0.05B | -31.75% |
| 2022-09-30 | $0.01B | $0.05B | 9.85% |
| 2022-06-30 | $0.01B | $0.05B | 18.27% |
| 2022-03-31 | $0.00B | $0.05B | 2.15% |
| 2021-12-31 | $0.00B | $0.05B | 6.56% |
| 2021-09-30 | $-0.02B | $0.05B | -38.20% |
| 2021-06-30 | $-0.03B | $0.05B | -55.67% |
| 2021-03-31 | $-0.03B | $0.06B | -47.06% |
| 2020-12-31 | $-0.03B | $0.06B | -48.13% |
| 2020-09-30 | $-0.03B | $0.06B | -49.59% |
| 2020-06-30 | $-0.03B | $0.06B | -45.90% |
| 2020-03-31 | $-0.03B | $0.06B | -44.64% |
| 2019-12-31 | $-0.03B | $0.06B | -44.44% |
| 2019-09-30 | $-0.03B | $0.06B | -39.22% |
| 2019-06-30 | $-0.02B | $0.07B | -33.92% |
| 2018-03-31 | $-0.01B | $0.01B | -126.32% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.210B | $0.019B |
| Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |